RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Completed · Phase 3

Conditions studied: Peripheral Artery Disease, Atherosclerosis, Artery Diseases, Peripheral, Plaque, Atherosclerotic, Occlusive Arterial Disease

In brief

To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA). Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

Key facts

Study ID

NCT03064126

Run by

Boston Scientific Corporation

People needed

440

Starts

2017-03-02

Expected to finish

2023-10-25

Last updated by the study team

2024-10-29

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits;
• Subject at least 20 years of age;
• Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4;
• Target lesion is in the native SFA and/or PPA down to the P1 segment;
• Patent popliteal and infrapopliteal arteries, i.e., single vessel runoff or better with at least one of three vessels patent (less than 50 % stenosis) to the ankle or foot;
• Reference vessel diameter ≥ 4 mm and ≤ 8 mm by visual estimate;
• Angiographic evidence that target lesion consists of a single de novo, non-stented and non-atherectomy treated or restenotic lesion (or tandem lesions or a combination lesion as defined below) that is:
• ≥ 70%-99% stenotic with total lesion length up to 180 mm by visual estimate.
• Occluded with total lesion length ≤ 100 mm by visual estimate.
• If lesion is restenotic, most recent PTA treatment must be > 3 months prior to enrollment.

You may not qualify if…

• Life expectancy, documented in the Investigator's opinion, of less than 12 months;
• Hemorrhagic stroke or cardiac event (e.g. STEMI, unstable angina) within 6 months prior to enrollment;
• Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel;
• Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated;
• Chronic renal insufficiency with serum creatinine > 2.0 mg/dL within 30 days of index procedure or treatment with dialysis;
• Platelet count < 80,000 mm 3 or > 600,000 mm 3 or history of bleeding diathesis;
• Receiving immunosuppressive therapy;
• Septicemia at the time of enrollment;
• Any major intervention planned within 30 days post index procedure;
• Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention within 30 days of enrollment;
• Failure to successfully cross the target lesion with a guidewire;
• Failure to successfully pre-dilate the target vessel;
• Patient has lesion that requires the use of adjunctive primary treatment modalities (i.e. laser, atherectomy, scoring/cutting balloon, other debulking devices, etc.) during the index procedure;
• History of major amputation in the target limb;
• Target lesion or vessel has ever been previously treated with stent (e.g. in-stent restenosis) or surgery. Target lesion or vessel has been treated with atherectomy or a DCB in the past 12 months;
• Pregnant or breast feeding;
• Presence of aneurysm in the target vessel;
• Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment;
• Patient has significant inflow disease which cannot be treated prior to the target lesion treatment;
• Patient has perforated targeted vessel as evidenced by extravasation of contrast media;
• Patient has severe calcification that renders the lesion undilatable;
• Current participation in another investigational drug or device clinical trial that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current trial endpoints.

Where it is running

• Rocky Mountain Regional VA Medical Center — Aurora, Colorado, United States
• The Vascular Experts — Stratford, Connecticut, United States
• Christiana Hospital — Newark, Delaware, United States
• Washington Hospital Center — Washington D.C., District of Columbia, United States
• South Florida Vascular Associates — Coconut Creek, Florida, United States
• North Florida Regional Medical Center — Gainesville, Florida, United States
• Mount Sinai Medical Center — Miami Beach, Florida, United States
• AdventHealth Orlando — Orlando, Florida, United States
• AdventHealth Sebring — Sebring, Florida, United States
• Wellstar Hospitals — Marietta, Georgia, United States
• Kaiser Foundation Hospitals — Honolulu, Hawaii, United States
• St. Joseph Hospital — Fort Wayne, Indiana, United States
• Community Hospital — Munster, Indiana, United States
• King's Daughters Medical Center - Kentucky Heart Institute — Ashland, Kentucky, United States
• Terrebonne General Medical Center — Houma, Louisiana, United States
• Mercy Hospital — Coon Rapids, Minnesota, United States
• United Heart and Vascular Clinic — Saint Paul, Minnesota, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Jersey Shore University Medical Center — Neptune City, New Jersey, United States
• Mount Sinai Medical Center — New York, New York, United States
• Staten Island University Hospital — Staten Island, New York, United States
• Rex Hospital — Raleigh, North Carolina, United States
• Coastal Carolina Surgical Associates — Wilmington, North Carolina, United States
• Bethesda North Hospital — Cincinnati, Ohio, United States
• Thomas Hospital — Fairhope, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.